Research programme : staphylococcal infections vaccine - Serenta Biotechnology

Drug Profile

Research programme : staphylococcal infections vaccine - Serenta Biotechnology

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Serenta Biotechnology
  • Class Bacterial vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Staphylococcal infections

Most Recent Events

  • 01 Jun 2017 Preclinical development for Staphylococcal infections (Prevention) in USA (Parenteral) before June 2017
  • 01 Jun 2017 Serenta in-licenses multivalent vaccine technology from University of Maryland and Northern Arizona University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top